Nanoview: Every journey starts with a single step.

ABOUT NANOVIEW BIOSCIENCES

NanoView Biosciences, founded in 2015 and acquired in 2022, was focused on enabling worldwide life science researchers to better understand the biological role of extracellular vesicles, including exosomes and viral vectors, and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease.

NanoView's proprietary products, including the ExoView® R100 and R200 platforms, had been designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision nanomedicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.

EVERY JOURNEY STARTS WITH A SINGLE STEP

NanoView holds a special place in our hearts at Prodct as they were our first long-term client. They were our “first step.”  Nanoview had developed a novel technology capable of unlocking unparalleled exosome and lentivirus characterization research globally. As they were rapidly approaching scaling the technology, products, and business, a member of their Board of Directors recommended they talk with Prodct to see if we could help.  

Long before NanoView was acquired, Prodct had been helping instill hardware and software product development best practices while implementing supportive QMS infrastructure and operations-minded tools designed to help scale the company as they grew. 

Prodct had become such an extension of the team that we’d consistently be invited to company picnics, home BBQs, and holiday parties. Not being perceived as external advisors but rather as trusted friends on the inside helps us realize our unique approach to supporting young companies like NanoView was working…   and we’ve maintained that spirit as we’ve grown.